- Home
- LNSR vs IMA Comparison
LNSR vs IMA Comparison
Compare LNSR & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LNSR | IMA |
|---|---|---|
| Founded | 2004 | 2019 |
| Country | United States | United States |
| Employees | N/A | 17 |
| Industry | Medical Electronics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.1M | 66.3M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | LNSR | IMA |
|---|---|---|
| Price | $5.62 | $5.79 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 90.2K | 8.4K |
| Earning Date | 05-11-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | ★ $58,435,000.00 | N/A |
| Revenue This Year | $10.06 | N/A |
| Revenue Next Year | $41.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.24 | N/A |
| 52 Week Low | $5.06 | $3.94 |
| 52 Week High | $13.32 | $17.50 |
Technical Indicators
Market Signals| Indicator | LNSR | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 43.53 |
| Support Level | $5.58 | $5.36 |
| Resistance Level | $6.20 | $6.13 |
| Average True Range (ATR) | 0.21 | 0.31 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 27.91 | 22.45 |
Price Performance
Historical ComparisonAbout LNSR LENSAR Inc.
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe, Asia (excluding South Korea), South Korea, and Other.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.